Dr. Harris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9609 Medical Center Drive
Bethesda, MD 20892Phone+1 240-276-6327
Summary
- Dr. Lyndsay Harris is a medical oncologist in in the Cancer Diagnosis Program at the National Cancer Institute. She received her medical degree from University of Alberta Faculty of Medicine and her Fellowship at Georgetown University. She has been in practice 35 years. She specializes in breast cancer and clinical informatics and is experienced in biomarkers and assays, molecular biology and genomics
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1991 - 1994
University of AlbertaClass of 1988
Certifications & Licensure
OH State Medical License 2012 - 2026
CT State Medical License 2006 - 2012
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2014
Clinical Trials
- Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2002 Apr 01
- A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Join now to see all
Publications & Presentations
PubMed
- Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D.Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, Li Chen, Michael J Overman
Clinical Cancer Research. 2024-12-13 - Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2024-12-07 - NCI workshop on ctDNA in cancer treatment and clinical care.Brian S Sorg, Jung S Byun, V Anne Westbrook, James V Tricoli, James H Doroshow
Journal of the National Cancer Institute. 2024-12-01
Journal Articles
- Effect of Capivasertib in Patients with an AKT1 E17K-Mutated TumorKevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
- The Challenge for Development of Valuable Immuno-Oncology BiomarkersArta M Monjazeb, Janice M Mehnert, Lyndsay N Harris, Clinical Cancer Research
Press Mentions
NCI-MATCH Cancer Trial Finds a Promising Signal for the AKT Inhibitor IpatasertibOctober 26th, 2022- ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as It Continues to Locate Patients with BRAF MutationsMarch 16th, 2022
- 12 Open Arms in NCI-MATCH Treatment Trial Await Patients with Advanced or Rare CancersApril 26th, 2021
- Join now to see all
Grant Support
- Targeted Combinations For Her2- Positive Breast Cancer BiologyNational Cancer Institute2008–2009
- P-2: Target Combinations For HER2 - Positive Breast CancerNational Cancer Institute2005–2007
- Core--Tissue And PathologyNational Cancer Institute2000–2002
- Erbb2/P53 And Taxane Chemotherapy For Breast CancerNational Cancer Institute1999–2000
Committees
- Co-chair, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
